Juan M. Sepúlveda-Sánchez

TL;DR: Galunisertib + lomustine failed to demonstrate improved OS relative to placebo + lmustine, and patients treated with galun isertib alone had fewer drug-related grade 3/4 adverse events compared with lomUSTine-treated patients.

TL;DR: Dacomitinib has a limited single-agent activity in recurrent glioblastoma with EGFR amplification and the detailed molecular characterization of the 4 patients with response in this trial can be useful to select patients who could benefit from dacomItinib.

TL;DR: Overall, this comprehensive cardiovascular monitoring for the TGF-β inhibitor LY2157299 did not detect medically relevant cardiac toxicity and hence supports the evaluation of LY 2157299 in future clinical trials.

TL;DR: The transcription of microtubule-associated protein TAU (MAPT), a gene that has been classically associated with neurodegenerative diseases, is epigenetically controlled by the balance between wt and mut IDH1/2 in mouse and human gliomas.

TL;DR: In this paper, the TGF-β inhibitor LY2157299 monohydrate was administered as monotherapy or in combination with lomustine (n = 26) for a first-in-human dose study with 67 glioma and 12 solid tumor patients.